Results 141 to 150 of about 53,296 (261)

Acute retinal necrosis during the systemic use of Janus kinase inhibitor. [PDF]

Int J Retina Vitreous
Watanabe D, Namba K, Hase K, Suzuki K, Ogino Y, Saito M, Iwata D, Mizuuchi K, Hiraoka M, Narita M, Kitaichi N, Kitaya N, Ishida S.   +12 more
europepmc   +1 more source

Short-term omalizumab as a potential rescue therapy for alopecia areata flares during Janus kinase inhibitor maintenance. [PDF]

JAAD Int
Wang Q, Cheng K, Lin JM, Tao K, Xu M, Zhang X, Tang S, Ni C, Wu W, Lin J.   +9 more
europepmc   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

A Successful Outcome of Upadacitinib Therapy in a Patient with Genital Erosive Fixed Drug Eruption: A Case Report

Clinical, Cosmetic and Investigational Dermatology
Changxia Li,1– 5,* Xiaobing Wang,1– 5,* Xinze Li,1– 5 Meiqin Xu,1– 5 Shuling Kong,1– 5 Xiaohua Tao,1– 5 Weijun Liu,1– 5 Haiping Wan1– 5 1Department of Dermatology, Dermatology Hospital of Jiangxi Province, Nanchang, Jiangxi, People’s ...
Li C, Wang X, Li X, Xu M, Kong S, Tao X, Liu W, Wan H   +7 more
doaj  

Content validation of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in Janus kinase inhibitor-experienced patients with myelofibrosis. [PDF]

J Patient Rep Outcomes
Cutts K, Cardellino A, Zhang S, Phiri K, Gelhorn H.   +4 more
europepmc   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs. [PDF]

J Vet Pharmacol Ther
Boerngen K, Patel Y, Pittorino M, Toutain CE.   +3 more
europepmc   +1 more source

Pathogen‐Specific Bloodstream Infections Associated With Tumour Necrosis Factor‐α Inhibitors, Vedolizumab and Ustekinumab in Inflammatory Bowel Disease: A Danish Nationwide Case‐Control Study 2010–2024

Alimentary Pharmacology &Therapeutics, EarlyView.
In this nationwide study of patients with inflammatory bowel disease, TNF inhibitor use was associated with higher bloodstream infection rates, whereas vedolizumab and ustekinumab was not. Associations differed by pathogen species, and concomitant glucocorticoid use was associated with higher infection rates.
Cæcilie Leding, Alessandra Meddis, Jon Gitz Holler, Johan Burisch, Thomas Benfield   +4 more
wiley   +1 more source

Janus Kinase Inhibitor: A Possible Cause of Hyperammonemic Encephalopathy? [PDF]

J Clin Neurol
Park JH, Kim DH.
europepmc   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source